GlassScriptPhysician profile
Ansley Thompson Coffey
NPI 1700255452
$9,971.79
in general payments reported to CMS, 2019-2025
33 companies · $2,262 in 2025
The $2,262 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,374 · 2022: $1,678 · 2023: $2,409 · 2024: $2,248 · 2025: $2,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,031 · Education: $888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,030.84 |
| Education | $888.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,466.34 | 2021-2025 | Tremfya, Remicade, Stelara |
| Abbvie INC. | $1,308.62 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $842.70 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $704.40 | 2023-2025 | Sotyktu |
| Amgen INC. | $632.71 | 2021-2025 | Otezla, Otezla |
| Leo Pharma INC. | $454.01 | 2021-2025 | Adbry, Anzupgo |
| Ucb, INC. | $445.19 | 2021-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $442.03 | 2023-2025 | Zoryve |
| Pfizer INC. | $421.58 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $415.11 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $367.71 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $328.56 | 2021-2025 | Cabtreo, Jublia, Siliq |
| Incyte Corporation | $322.50 | 2022-2025 | Opzelura, Opzelura |
| Genzyme Corporation | $275.25 | 2021-2025 | |
| Lilly USA, LLC | $272.04 | 2021-2025 | Taltz, Ebglyss, Olumiant |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $235.16 | 2022 | |
| Galderma Laboratories, L.P. | $181.84 | 2021-2025 | Nemluvio |
| Vyne Pharmaceuticals INC. | $131.13 | 2021 | |
| Almirall LLC | $94.29 | 2022 | |
| Dermavant Sciences, INC. | $90.93 | 2022-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.03 | 2025 | Spevigo |
| Sanofi-Aventis U.S. LLC | $85.00 | 2025 | |
| Mayne Pharma Commercial LLC | $81.29 | 2021-2023 | |
| Allergan, INC. | $56.96 | 2021-2022 | |
| Organon LLC | $56.83 | 2025 | Hadlima, Vtama |
| Medline Industries LP | $44.33 | 2023 | |
| Merck Sharp & Dohme LLC | $21.07 | 2025 | Keytruda Qlex, Keytruda |
| Fresenius Kabi USA, LLC | $20.09 | 2023 | |
| Botanix Sb INC | $19.52 | 2025 | Sofdra |
| Medtronic, INC. | $18.91 | 2022 | |
| Epi Health, LLC | $18.68 | 2021 | |
| Verrica Pharmaceuticals INC. | $13.81 | 2025 | Ycanth |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ansley Coffey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.